Sino Biological's influenza virus research reagents
The influenza virus is an RNA virus that causes acute respiratory diseases and outbreaks in human populations due to its strong infectivity. According to the WHO, influenza results in approximately 1 billion infections and about 290,000 to 650,000 deaths worldwide each year. Vaccination is the most effective strategy to prevent influenza virus infection and its severe complications. However, the influenza virus is prone to mutation, and the circulating strains vary from year to year. Each year, vaccine manufacturers develop and produce influenza vaccines based on the strains recommended by the WHO.
Our company provides comprehensive influenza vaccine development services and production solutions to vaccine manufacturers. We offer a wide range of research reagents for influenza viruses, including influenza vaccine antigens, antibody pairs, neutralizing antibodies, and kits. Additionally, we provide high-quality technical services such as kit development, antigen expression, and antibody development. These products and services are suitable for various vaccine development scenarios, including screening of vaccine candidate strains, preparation of virus seed batches, evaluation of vaccine safety and immunogenicity, and assessment of vaccine protective effects.
